Tokyo, Dec 16 (UNI) Japan's pharmaceutical company Shionogi (Shionogi & Co) on Wednesday announced the launch of clinical trials of its prophylactic vaccine candidate against COVID-19.
"Shionogi & Co, Ltd announced that Shionogi has initiated a Japanese Phase 1/2 clinical trial of a prophylactic vaccine candidate for COVID-19, caused by the novel coronavirus (SARS-CoV-2) infection, and the first dose has been administered successfully," Sputnik quoted a statement by the company as saying.
Since April 2020, Shionogi has been pursuing the discovery and development of a recombinant protein vaccine against COVID-19, using a unique technology, dubbed BEVS, established by UMN Pharma Inc., a subsidiary of Shionogi.